소비자 건강 계약제조 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 서비스별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Consumer Health Contract Manufacturing Market Growth & Trends:

The global consumer health contract manufacturing market size is expected to reach USD 209.22 billion by 2030, growing at a CAGR of 8.72% from 2025 to 2030, according to a new report by Grand View Research, Inc. Currently, most of the pharmaceutical & biopharmaceutical, nutraceutical, cosmeceutical, and medical device companies prioritize efficiency and cost-effective solution to enhance profitability; hence, outsourcing manufacturing has become essential for cost optimization, regulatory compliance, and improved production capabilities. Moreover, several benefits are offered to healthcare companies, such as the ability to utilize contract manufacturing (CMO) facilities to streamline production and the opportunity to focus on core competencies and drive market growth. Besides, the rising requirement for clean-label formulations and consumers' increasing interest in functional supplements drive innovation in nutraceutical and OTC drug manufacturing.

In addition, shifting consumer preferences toward self-care is one of the significant factors for the rising demand for consumer health products that have fueled the demand for consumer health contract manufacturing. Besides, the market is experiencing rapid expansion driven by rising demand for OTC drugs, dietary supplements, cosmeceuticals, and medical devices. In addition, the rising e-commerce and distribution platforms have led to an increasing need for scalable and flexible manufacturing solutions. Furthermore, stringent regulations from bodies like the FDA, EMA, and GMP have led manufacturers to implement advanced quality control measures, serialization, and compliance-driven production.

Furthermore, the incorporation of advanced technologies, including AI-driven automation, real-time production monitoring, and blockchain-based traceability, is strengthening supply chain efficiency in manufacturing. Contract manufacturing organizations (CMOs) increasingly adopt advanced technologies such as continuous manufacturing, automation, and AI-powered process optimization to advance pharmaceutical production. These technological integrations enhance efficiency, reduce waste, and improve product quality and regulatory compliance.

Likewise, strategic initiatives and accelerating product launches drive the market. For instance, in August 2024, Aenova announced the development of a new gummy production line at its Romania facility. With the rising popularity of gummies as a preferred dosage form for food supplements and pharmaceuticals, the company plans to launch the line by the end of 2024. The new line is projected to have an annual production capacity of approximately one billion gummies. Such initiatives are expected to drive the market over the estimated time period.

Consumer Health Contract Manufacturing Market Report Highlights:

• Based on product, the over-the-counter (OTC) drugs segment dominated the market, with a share of 33.25% in 2024. This growth is driven by increased OTC drug production, rising self-medication trends, growing healthcare awareness, expanding e-commerce channels, and growing launches of OTC drugs in the market
• Based on service, the API manufacturing segment held the largest market share in 2024, attributed to the increasing requirements demand for OTC drugs. Besides, innovations in drug development have increased the need for contract manufacturing organizations (CMOs) for their efficiency, scalability, and adherence to regulatory standards, further fueling market expansion
• Based on end-use, the pharmaceutical & biopharmaceutical companies segment held the largest market share in 2024. These companies utilize CMO services to reduce production costs, enhance scalability, and accelerate product time-to-market. CMOs offer specialized manufacturing expertise for comprehensive product development. Outsourcing manufacturing services further provides access to innovative technologies, adaptable production capabilities, and optimized global supply chain management
• Asia Pacific is expected to register the fastest growth rate of 9.48% CAGR over the forecast period due to the rising number of healthcare companies and contract manufacturing organizations(CMOs) in countries such as Japan, China, and India. In addition, the availability of a skilled workforce at comparatively lower costs than in the U.S. is expected to significantly contribute to the market's expansion in this region

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Consumer Health Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technological Advancements
• 3.4. Pricing Model Analysis
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Analysis
  • 3.5.2. PESTEL by SWOT Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Consumer Health Contract Manufacturing Market: Product Estimates & Trend Analysis

• 4.1. Consumer Health Contract Manufacturing Market, By Product: Segment Dashboard
• 4.2. Consumer Health Contract Manufacturing Market, By Product: Movement Analysis
• 4.3. Consumer Health Contract Manufacturing Market Estimates & Forecasts, By Product, 2018 - 2030
• 4.4. Over-the-counter (OTC) Drugs
  • 4.4.1. Over-the-counter (OTC) Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Nutritional Supplements
  • 4.5.1. Nutritional Supplements Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Personal Care Products
  • 4.6.1. Personal Care Products Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Medical Devices
  • 4.7.1. Medical Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Consumer Health Contract Manufacturing Market: Service Estimates & Trend Analysis

• 5.1. Consumer Health Contract Manufacturing Market, By Service: Segment Dashboard
• 5.2. Consumer Health Contract Manufacturing Market, By Service: Movement Analysis
• 5.3. Consumer Health Contract Manufacturing Market Estimates & Forecasts, By Service, 2018 - 2030
• 5.4. API Manufacturing
  • 5.4.1. API Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Finished Dose Manufacturing
  • 5.5.1. Finished Dose Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Medical Device Manufacturing
  • 5.6.1. Medical Device Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Packaging & Labelling
  • 5.7.1. Packaging & Labelling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Consumer Health Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 6.1. Consumer Health Contract Manufacturing Market, By End Use: Segment Dashboard
• 6.2. Consumer Health Contract Manufacturing Market, By End Use: Movement Analysis
• 6.3. Consumer Health Contract Manufacturing Market Estimates & Forecasts, By End Use, 2018 - 2030
• 6.4. Pharmaceutical & Biopharmaceutical Companies
  • 6.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Nutraceutical Companies
  • 6.5.1. Nutraceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Cosmeceutical Companies
  • 6.6.1. Cosmeceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Medical Device Companies
  • 6.7.1. Medical Device Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Consumer Health Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. U.S
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Thailand
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Australia
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Share Analysis, 2023/24
• 8.3. Company Profiles
  • 8.3.1. Lonza
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Recipharm AB
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Piramal Consumer Products
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Scapa Healthcare
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Catalent, Inc
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. SCN BestCo
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Aenova Group
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Ventiz Healthcare
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Bionova
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Aurohealth
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Siegrified AG
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Thermo Fisher Scientific Inc
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives
  • 8.3.13. Famar
    • 8.3.13.1. Company Overview
    • 8.3.13.2. Financial Performance
    • 8.3.13.3. Service Benchmarking
    • 8.3.13.4. Strategic Initiatives
  • 8.3.14. Sirio Pharma Co., Ltd
    • 8.3.14.1. Company Overview
    • 8.3.14.2. Financial Performance
    • 8.3.14.3. Service Benchmarking
    • 8.3.14.4. Strategic Initiatives
  • 8.3.15. Tishcon Corporation
    • 8.3.15.1. Company Overview
    • 8.3.15.2. Financial Performance
    • 8.3.15.3. Service Benchmarking
    • 8.3.15.4. Strategic Initiatives
  • 8.3.16. Vit-Best Nutrition Inc
    • 8.3.16.1. Company Overview
    • 8.3.16.2. Financial Performance
    • 8.3.16.3. Service Benchmarking
    • 8.3.16.4. Strategic Initiatives